313 related articles for article (PubMed ID: 20026811)
1. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.
Lai MN; Wang SM; Chen PC; Chen YY; Wang JD
J Natl Cancer Inst; 2010 Feb; 102(3):179-86. PubMed ID: 20026811
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid.
Wang SM; Lai MN; Wei A; Chen YY; Pu YS; Chen PC; Wang JD
PLoS One; 2014; 9(8):e105218. PubMed ID: 25170766
[TBL] [Abstract][Full Text] [Related]
3. Re: Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.
Su YC; Lin JS; Lee MT; Li TC; Lee SM
J Natl Cancer Inst; 2010 Jul; 102(13):988; author reply 988-90. PubMed ID: 20479292
[No Abstract] [Full Text] [Related]
4. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study.
Lai MN; Lai JN; Chen PC; Hsieh SC; Hu FC; Wang JD
Am J Kidney Dis; 2010 Mar; 55(3):507-18. PubMed ID: 20116155
[TBL] [Abstract][Full Text] [Related]
5. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid.
Lai MN; Lai JN; Chen PC; Tseng WL; Chen YY; Hwang JS; Wang JD
Nephrology (Carlton); 2009 Apr; 14(2):227-34. PubMed ID: 19076288
[TBL] [Abstract][Full Text] [Related]
6. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
7. Risk assessment of upper tract urothelial carcinoma related to aristolochic acid.
Wu F; Wang T
Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):812-20. PubMed ID: 23462915
[TBL] [Abstract][Full Text] [Related]
8. Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists.
Yang HY; Wang JD; Lo TC; Chen PC
J Urol; 2013 Jan; 189(1):48-52. PubMed ID: 23164394
[TBL] [Abstract][Full Text] [Related]
9. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
Chen CJ; Yang YH; Lin MH; Lee CP; Tsan YT; Lai MN; Yang HY; Ho WC; Chen PC;
Int J Cancer; 2018 Oct; 143(7):1578-1587. PubMed ID: 29667191
[TBL] [Abstract][Full Text] [Related]
10. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
Dickman KG; Chen CH; Grollman AP; Pu YS
World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
[TBL] [Abstract][Full Text] [Related]
11. Reduction in the Incidence of Urological Cancers after the Ban on Chinese Herbal Products Containing Aristolochic Acid: An Interrupted Time-Series Analysis.
Jhuang JR; Chiang CJ; Su SY; Yang YW; Lee WC
Sci Rep; 2019 Dec; 9(1):19860. PubMed ID: 31882686
[TBL] [Abstract][Full Text] [Related]
12. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi).
Nortier JL; Martinez MC; Schmeiser HH; Arlt VM; Bieler CA; Petein M; Depierreux MF; De Pauw L; Abramowicz D; Vereerstraeten P; Vanherweghem JL
N Engl J Med; 2000 Jun; 342(23):1686-92. PubMed ID: 10841870
[TBL] [Abstract][Full Text] [Related]
13. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
14. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
Grollman AP
Environ Mol Mutagen; 2013 Jan; 54(1):1-7. PubMed ID: 23238808
[TBL] [Abstract][Full Text] [Related]
15. [Aristolochic acid nephropathy ("Chinese herb nephropathy")].
Nortier J; Pozdzik A; Roumeguere T; Vanherweghem JL
Nephrol Ther; 2015 Dec; 11(7):574-88. PubMed ID: 26515658
[TBL] [Abstract][Full Text] [Related]
16. Aristolochic acid and its effect on different cancers in uro-oncology.
Rebhan K; Ertl IE; Shariat SF; Grollman AP; Rosenquist T
Curr Opin Urol; 2020 Sep; 30(5):689-695. PubMed ID: 32701724
[TBL] [Abstract][Full Text] [Related]
17. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up.
Lemy A; Wissing KM; Rorive S; Zlotta A; Roumeguere T; Muniz Martinez MC; Decaestecker C; Salmon I; Abramowicz D; Vanherweghem JL; Nortier J
Am J Kidney Dis; 2008 Mar; 51(3):471-7. PubMed ID: 18295063
[TBL] [Abstract][Full Text] [Related]
18. Non-aristolochic acid prescribed Chinese herbal medicines and the risk of mortality in patients with chronic kidney disease: results from a population-based follow-up study.
Hsieh CF; Huang SL; Chen CL; Chen WT; Chang HC; Yang CC
BMJ Open; 2014 Feb; 4(2):e004033. PubMed ID: 24561496
[TBL] [Abstract][Full Text] [Related]
19. Occupational kidney disease among Chinese herbalists exposed to herbs containing aristolochic acids.
Yang HY; Wang JD; Lo TC; Chen PC
Occup Environ Med; 2011 Apr; 68(4):286-90. PubMed ID: 20935286
[TBL] [Abstract][Full Text] [Related]
20. Detection of a negative correlation between prescription of Chinese herbal products containing coumestrol, genistein or daidzein and risk of subsequent endometrial cancer among tamoxifen-treated female breast cancer survivors in Taiwan between 1998 and 2008: A population-based study.
Hu YC; Wu CT; Lai JN; Tsai YT
J Ethnopharmacol; 2015 Jul; 169():356-62. PubMed ID: 25934515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
